A Mitchell Phelps, PhD
College of Pharmacy
Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin, Biliary Tract Cancer, Lymphoma, Mantle-Cell
Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU. Their work aims to understand the mechanisms involved in the absorption, distribution, metabolism, and excretion (i.e. pharmacokinetics, PK) of these agents, and how both the PK and pharmacodynamic (PD) effects of these agents are altered by genetic differences (polymorphisms) among individuals (i.e. pharmacogenetics, PG).